| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Specialty Pharmaceutical Industry - 2011 Yearbook
Specialty Pharmaceutical Industry - 2011 Yearbook
HIV/AIDS and Rheumatoid Arthritis are the Major Indications, Which Will Drive the Specialty Pharmaceutical Market in the Future
London,
London,
United Kingdom
(prbd.net)
17/05/2011
The Specialty pharmaceutical market is dominated by rheumatoid arthritis and HIV/AIDS in the year 2009. Rheumatoid arthritis accounted for 26% of the total market, while HIV/AIDS closely followed it with a market share of 25%. Alzheimer’s disease, Attention Deficit Hyperactive Disorder (ADHD) and epilepsy have also shown strong market presence, holding shares of 14%, 8% and 7% respectively in 2009.
The global HIV/AIDS market has witnessed a strong growth over the past few years. According to GBI Research analysis, the market is estimated to grow at a steady rate of 3% between 2009 and 2017. Increased disease awareness levels have increased treatment seeking and diagnosed populations in the US, Europe and Japan. Furthermore the progress in HIV treatment and introduction of Highly Active Antiretroviral Therapy (HAART) and other effective drugs have contributed effectively to the market growth.
On the other hand the global rheumatoid arthritis market also has recorded a strong growth over the past few years. GBI Research forecasts the market to grow at a better compound annual growth rate (CAGR) of 8.6% between 2009 and 2017. The major drivers for the growth of the rheumatoid arthritis therapeutics market are the increase in the incidence rate and prevalence rate. The introduction of state-of-the-art diagnostic tools to detect rheumatoid arthritis at an early stage is another factor that will be driving the growth of this market.
For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Specialty-Pharmaceutical-Industry-2011-Yearbook&Title=Pharmac&ReportType=Industry_Report
In addition age related macular degeneration market has grown historically at high growth rate and it is expected to grow at approximately 10% between 2009 and 2017. Increasing diseased population and diagnosis rates are the major drivers of the market growth.
The specialty pharmaceutical market pipeline for the eight conditions has 2,800 molecules in the collective pipeline. The pipeline is active with many new promising molecules and it is dominated by colorectal cancer, followed by Glaucoma and Alzheimer’s disease.
GBI Research, the leading business intelligence provider has released its latest research
“Specialty Pharmaceutical Industry - 2011 Yearbook”, which essentially provides insights on specialty pharmaceutical sales and price forecasts until 2017. The report provides in-depth therapeutics analysis of eight niche indications, namely: Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), colorectal cancer, epilepsy, glaucoma, Human Immunodeficiency Virus (HIV)/Acquired immune deficiency syndrome (AIDS), macular degeneration and rheumatoid arthritis, including their annual cost of therapy (ACT) and revenue. In addition, the geographicalm distribution of these disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the specialty
pharmaceutical Research and Development (R&D) pipeline and the potential future blockbusters up to 2017. Furthermore, it also covers the market forecasts and treatment usage patterns of these eight therapeutic indications up to 2017. Finally, the key trend analysis on Mergers and Acquisitions (M&A), licensing agreements and co-development deals involving specialty pharmaceuticals is also presented.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Specialty-Pharmaceutical-Industry-2011-Yearbook&Title=Pharmac&ReportType=Industry_Report
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|